Ocugen (Ocugen) Dividend Payout Ratio : 0.00 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ocugen Dividend Payout Ratio?

Ocugen's dividend payout ratio for the months ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Ocugen's Dividend Payout Ratio or its related term are showing as below:

OCGN's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-03), the Dividend Yield % of Ocugen is 0.00%.

Ocugen's Dividends per Share for the months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Ocugen Dividend Payout Ratio Historical Data

The historical data trend for Ocugen's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Dividend Payout Ratio Chart

Ocugen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

Ocugen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Ocugen's Dividend Payout Ratio

For the Biotechnology subindustry, Ocugen's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocugen's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Ocugen's Dividend Payout Ratio falls into.

Ocugen Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Ocugen's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-0.26
	=	N/A

Ocugen's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.05
	=	N/A

Ocugen (NAS:OCGN) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Ocugen Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Ocugen's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocugen (Ocugen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

OCGN:Mexico 2H51:Germany

Address

11 Great Valley Parkway, Malvern, PA, USA, 19355

Website

https://www.ocugen.com

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Executives

Junge Zhang	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Quan Anh Vu	officer: CFO/CBO	22616 ERWIN STREET, WOODLAND HILLS CA 91367
Shankar Musunuri	director, officer: Chief Executive Officer	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Arun Upadhyay	officer: Chief Scientific Officer	C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355
Ramesh Kumar	director	375 PHEASANT RUN, NEWTOWN PA 18940
Kirsten Castillo	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Uday Kompella	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Prabhavathi Fernandes	director	114 MILTON AVENUE, CHAPEL HILL NC 27514
Marna C Whittington	director	2959 BARLEY MILL ROAD, YORKLYN DE 19736
Jessica Crespo	officer: CAO/SVP, Finance	C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355
Sanjay Subramanian	officer: Chief Financial Officer	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Manish Potti	director	C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355
Vijay Tammara	officer: Vice President	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Suha Taspolatoglu	director	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Kelly Beck	officer: Vice President	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355